Immunomedics Inc – ‘NT 10-K’ for 6/30/99

On:  Tuesday, 9/28/99   ·   For:  6/30/99   ·   Accession #:  722830-99-9   ·   File #:  0-12104

in

this entire Filing. an “Entity” Search.

Show

Documents searched

and

each “hit”. the 1st “hit”.

↓↑Hints

Notice of a Late Filing of a Form 10-K   —   Form 12b-25
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: NT 10-K     Notice of a Late Filing of a Form 10-K                 3     12K 

NT 10-K
1st Page of 3
TOC
↑Top
Previous
Next
↓Bottom
Just 1st
 
U.S. SECURITIES AND EXCHANGE COMMISSION 
WASHINGTON, D.C. 20549

 FORM 12b-25
 SEC FILE NUMBER

_______________                                                                 
SEC FILE NUMBER                                                                 
1-12204                                                                   
===============            NOTIFICATION OF LATE FILING                          
CUSIP NUMBER                                                                    
452907108                                                                   

(Check One): [X] Form 10-K and Form 10-KSB [ ] Form 20-F [ ] Form 11-K
[ ] Form 10-Q and Form 10-QSB [ ] Form N-SAR

For Period Ended: June 30, 1999                               

[ ] Transition Report on Form 10-K                            
[ ] Transition Report on Form 20-F                            
[ ] Transition Report on Form 11-K                            
[ ] Transition Report on Form 10-Q                            
[ ] Transition Report on Form N-SAR                           

For the Transition Period Ended:                              

Read Attached Instruction Sheet Before Preparing Form. Please Print or Type.    

Nothing  in this  form  shall be  construed  to imply  that the  Commission  has
verified any information contained herein.                                      

If the notification  relates to a portion of the filing checked above,  identify
the Item(s) to which the notification relates:                                  

Part I -- Registrant Information                                                

Full Name of Registrant: Immunomedics, Inc.                                     

Former Name if Applicable:                                                      

Address of Principal Executive Office (Street and Number): 300 American Road    
City, State and Zip Code                    Morris Plains, NJ 07950             

NT 10-K
2nd Page of 3
TOC
1st
Previous
Next
↓Bottom
Just 2nd
Part II -- Rules 12b-25 (b) and (c)                                             

If the subject report could not be filed without  unreasonable effort or expense
and the registrant seeks relief pursuant to Rule 12b-25(b), the following should
be completed. (Check box if appropriate)                                        

         (a)      The reasons described in reasonable detail in Part III of this
                  form could not be eliminated  without  unreasonable  effort or
expense;                                    

[x]      (b)      The  subject  annual  report,  semi-annual  report, transition
                  report on Form 10-K, Form 20-F, 11-K or Form N-SAR, or portion
                  thereof will be filed on or before the fifteenth  calendar day
                  following the  prescribed  due date; or the subject  quarterly
                  report or transition  report on Form 10-Q, or portion  thereof
                  will be filed on or before the fifth  calendar  day  following
the prescribed due date; and                

         (c)      The  accountant's  statement or other exhibit required by Rule
12b-25(c) has been attached if applicable.  

Part III -- Narrative                                                           

State below in  reasonable  detail the  reasons  why Form 10-K and Form  10-KSB,
20-F,  11-K, 10-Q and Form 10-QSB,  N-SAR,  or the transition  report or portion
thereof could not be filed within the prescribed period.                        

The Registrant is currently in discussions with a representative  of the holders
of the Company's Series F Preferred Stock concerning a possible restructuring of
certain terms of their  investment.  Until such  discussions are completed,  the
Registrant will be unable to finalize its financial statements.                 

Part IV -- Other Information                                                    

         (1) Name  and  telephone  number of person to contact in regard to this
notification                                                                    

Sal Asher                        (973)            605-8200            
(Name)                        (Area Code)    (Telephone Number)       

         (2) Have all other periodic  reports required under section 13 or 15(d)
of the Securities  Exchange Act of 1934 or section 30 of the Investment  Company
Act of 1940 during the  preceding 12 months or for such shorter  period that the
registrant was required to file such report(s) been filed?  If the answer is no,
identify report(s).                                                             
                                                                [x] Yes   [ ] No

         (3) Is it  anticipated  that  any  significant  change  in  results  of
operations  from the  corresponding  period  for the last  fiscal  year  will be
reflected by the  earnings  statements  to be included in the subject  report or
portion thereof?                                                                
                                                                [x] Yes   [ ] No

If so: attach an explanation of the  anticipated  change,  both  narratively and
quantitatively, and, if appropriate, state the reasons why a reasonable estimate
of the results cannot be made.                                                  

The Registrant  expects to report revenues of $7.6 million,  which include a 50%
increase in product sales, and a net loss of $11.2 million,  or $0.31 per share,
for the fiscal  year ended June 30,  1999.  This  compares  to  revenues of $7.6
million and a net loss of $11.8  million,  or $0.32 per share,  for fiscal 1998.
Revenues  for  fiscal  1998,   included  $1.8  million,   or  $0.05  per  share,
representing  settlement of a dispute with Pharmacia & Upjohn ("Pharmacia") that
originated  when  Pharmacia  terminated  its marketing  and product  development
contract with the Registrant.                                                   

 2

NT 10-K
Last Page of 3
TOC
1st
Previous
Next
↓Bottom
Just 3rd
IMMUNOMEDICS, INC.
(Name of Registrant as specified in charter)

has  caused  this  notification  to be signed on its  behalf by the  undersigned
thereunto duly authorized.                                                      

Date September 28, 1999                     By: /s David M. Goldenberg          
                                                --------------------------------
                                   David M. Goldenberg
                                              Chairman and Chief Executive
                           Officer

INSTRUCTION: The form may be signed by an executive officer of the registrant or
by any other duly  authorized  representative.  The name and title of the person
signing  the form  shall  be typed or  printed  beneath  the  signature.  If the
statement is signed on behalf of the registrant by an authorized  representative
(other than an executive officer), evidence of the representative's authority to
sign on behalf of the registrant shall be filed with the form.                  

 ATTENTION

Intentional  misstatements  or omissions  of fact  constitute  Federal  Criminal
Violations (See 18 U.S.C. 1001).                                                

 3

Dates Referenced Herein   and   Documents Incorporated by Reference

				Referenced-On Page
This ‘NT 10-K’ Filing		Date		First		Last			Other Filings
Filed on:		9/28/99		3
For Period End:		6/30/99		1		2			10-K
									List all Filings